Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to 10.79%.

  • Arrowhead Pharmaceuticals' EBITDA Margin rose 70440300.0% to 10.79% in Q4 2025 from the same period last year, while for Dec 2025 it was 21.64%, marking a year-over-year increase of 257873600.0%. This contributed to the annual value of 3.83% for FY2025, which is 169489500.0% up from last year.
  • Arrowhead Pharmaceuticals' EBITDA Margin amounted to 10.79% in Q4 2025, which was up 70440300.0% from 6.71% recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' 5-year EBITDA Margin high stood at 67.83% for Q1 2025, and its period low was 7033.24% during Q4 2024.
  • Its 5-year average for EBITDA Margin is 808.98%, with a median of 165.88% in 2021.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' EBITDA Margin crashed by -36899000bps in 2023, and later surged by 70440300bps in 2025.
  • Arrowhead Pharmaceuticals' EBITDA Margin (Quarter) stood at 229.28% in 2021, then skyrocketed by 71bps to 67.04% in 2022, then tumbled by -5504bps to 3756.94% in 2023, then tumbled by -87bps to 7033.24% in 2024, then surged by 100bps to 10.79% in 2025.
  • Its EBITDA Margin was 10.79% in Q4 2025, compared to 6.71% in Q3 2025 and 639.91% in Q2 2025.